<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">03720</article-id><article-id pub-id-type="doi">10.7554/eLife.03720</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group></article-categories><title-group><article-title>Neuropilin-1 functions as a VEGFR2 co-receptor to guide developmental angiogenesis independent of ligand binding</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-15537"><name><surname>Gelfand</surname><given-names>Maria V</given-names></name><aff><addr-line><named-content content-type="department">Department of Neurobiology</named-content></addr-line>, <institution>Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15538"><name><surname>Hagan</surname><given-names>Nellwyn</given-names></name><aff><addr-line><named-content content-type="department">Department of Neurobiology</named-content></addr-line>, <institution>Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15539"><name><surname>Tata</surname><given-names>Aleksandra</given-names></name><aff><addr-line><named-content content-type="department">Department of Neurobiology</named-content></addr-line>, <institution>Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15540"><name><surname>Oh</surname><given-names>Won-Jong</given-names></name><aff><addr-line><named-content content-type="department">Department of Neurobiology</named-content></addr-line>, <institution>Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15541"><name><surname>Lacoste</surname><given-names>Baptiste</given-names></name><aff><addr-line><named-content content-type="department">Department of Neurobiology</named-content></addr-line>, <institution>Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15542"><name><surname>Kang</surname><given-names>Kyu-Tae</given-names></name><aff><addr-line><named-content content-type="department">Vascular Biology Program</named-content></addr-line>, <institution>Boston Children's Hospital, Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-18980"><name><surname>Kopycinska</surname><given-names>Justyna</given-names></name><aff><addr-line><named-content content-type="department">Department of Neurobiology</named-content></addr-line>, <institution>Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15543"><name><surname>Bischoff</surname><given-names>Joyce</given-names></name><aff><addr-line><named-content content-type="department">Vascular Biology Program</named-content></addr-line>, <institution>Boston Children's Hospital, Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-14719"><name><surname>Wang</surname><given-names>Jia-Huai</given-names></name><aff><addr-line><named-content content-type="department">Department of Medical Oncology</named-content></addr-line>, <institution>Dana-Farber Cancer Institute, Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-9212"><name><surname>Gu</surname><given-names>Chenghua</given-names></name><aff><addr-line><named-content content-type="department">Department of Neurobiology</named-content></addr-line>, <institution>Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country><email>Chenghua_Gu@hms.harvard.edu</email></aff><xref ref-type="fn" rid="conf1"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1147"><name><surname>Nathans</surname><given-names>Jeremy</given-names></name><role>Reviewing editor</role><aff><institution>Howard Hughes Medical Institute, Johns Hopkins University School of Medicine</institution>, <country>United States</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>22</day><month>09</month><year>2014</year></pub-date><volume>3</volume><elocation-id>e03720</elocation-id><supplementary-material><ext-link xlink:href="elife-03720-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>18</day><month>06</month><year>2014</year></date><date date-type="accepted"><day>20</day><month>09</month><year>2014</year></date></history><permissions><copyright-statement>Copyright Â© 2014, Gelfand et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Gelfand et al</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>During development, tissue repair, and tumor growth, most blood vessel networks are generated through angiogenesis. Vascular endothelial growth factor (VEGF) is a key regulator of this process and currently, both VEGF and its receptors, VEGFR1, VEGFR2, and Neuropilin1 (NRP1), are targeted in therapeutic strategies for vascular disease and cancer. NRP1 is essential for vascular morphogenesis, but how NRP1 functions to guide vascular development has not been completely elucidated. Here, we generated a mouse line harboring a point mutation in the endogenous Nrp1 locus that selectively abolishes VEGF-NRP1 binding <italic>(Nrp1<sup>VEGF-</sup>). Nrp1<sup>VEGF-</sup></italic> mutants survive to adulthood with normal vasculature revealing that NRP1 functions independent of VEGF-NRP1 binding during developmental angiogenesis. Moreover, we found that <italic>Nrp1</italic>-deficient vessels have reduced VEGFR2 surface expression in vivo demonstrating that NRP1 regulates its co-receptor, VEGFR2. Given the resources invested in NRP1 targeted anti-angiogenesis therapies, our results will be integral for developing strategies to re-build vasculature in disease.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All animals were handled according to approved institutional animal care and use committee (IACUC) protocols at Harvard Medical School (IACUC Study ID: IS00000045).</p></fn></fn-group></back></article>